MedTrace Logo

ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy

NCT04513600 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2021-01-27

No results posted yet for this study

Summary

The study will investigate the stabilization effects of Tafamidis utilizing cardiac imaging cardiac magnetic resonance imaging (CMR). The investigators propose to pursue the following specific aims:

1. Utilize cardiac magnetic resonance to assess stabilization of ATTR after Tafamidis therapy based on extracellular volume mapping.
2. Investigate left ventricular myocardial mass, native T1, T2, and extracellular volume mapping after 12 month follow-up.
3. Utilize cardiac magnetic resonance feature tracking at baseline and at 12 month follow-up.

Conditions

  • Transthyretin Amyloidosis

Interventions

DIAGNOSTIC_TEST

Cardiac MRI

Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Ohio State University

    collaborator OTHER

  • The Christ Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-08-01
Completion
2023-08-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513600 on ClinicalTrials.gov